Related references
Note: Only part of the references are listed.Polycomb Gene Silencing Mechanisms: PRC2 Chromatin Targeting, H3K27me3 'Readout', and Phase Separation-Based Compaction
Yiran Guo et al.
TRENDS IN GENETICS (2021)
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150)
Andrew H. Wei et al.
BLOOD CANCER JOURNAL (2021)
Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis
Romain Vazquez et al.
BLOOD CANCER JOURNAL (2021)
Engineering Stem Cell Factor Ligands with Different c-Kit Agonistic Potencies
Tal Tilayov et al.
MOLECULES (2020)
Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia
Kai Chen et al.
CELL DEATH & DISEASE (2020)
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Jenna L. Carter et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Epigenetic Modulation of Self-Renewal Capacity of Leukemic Stem Cells and Implications for Chemotherapy
Richard L. Momparler et al.
EPIGENOMES (2020)
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
Andrew H. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Emerging Roles for Polycomb-Group Proteins in Stem Cells and Cancer
Ho Lam Chan et al.
TRENDS IN BIOCHEMICAL SCIENCES (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo
Yongwei Su et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo
Shijun Wen et al.
CANCER LETTERS (2018)
Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells
Mohamed Rahmani et al.
CANCER RESEARCH (2018)
RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia
S. Rudat et al.
LEUKEMIA (2018)
Shutting Down Acute Myeloid Leukemia and Myelodysplastic Syndrome with BCL-2 Family Protein Inhibition
Prashant Sharma et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2018)
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
Daniel A. Pollyea et al.
NATURE MEDICINE (2018)
CD117/c-kit in Cancer Stem Cell-Mediated Progression and Therapeutic Resistance
Brittni M. Foster et al.
BIOMEDICINES (2018)
CD117 expression is a predictive marker for poor prognosis in patients with non-small cell lung cancer
Tomohiko Sakabe et al.
ONCOLOGY LETTERS (2017)
Inhibition of EZH2 Promotes Human Embryonic Stem Cell Differentiation into Mesoderm by Reducing H3K27me3
Yongxin Yu et al.
STEM CELL REPORTS (2017)
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells
Xiaojia Niu et al.
CLINICAL CANCER RESEARCH (2016)
Targeting EZH2 in cancer
Kimberly H. Kim et al.
NATURE MEDICINE (2016)
Acute myeloid leukemia: a comprehensive review and 2016 update
I. De Kouchkovsky et al.
BLOOD CANCER JOURNAL (2016)
Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
Maryam Abbaspour Babaei et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Targeting EZH2 and PRC2 dependence as novel anticancer therapy
Bowen Xu et al.
EXPERIMENTAL HEMATOLOGY (2015)
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Shundong Cang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies
G. S. Choudhary et al.
CELL DEATH & DISEASE (2015)
Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
X. Niu et al.
LEUKEMIA (2014)
Whole Blood Gene Expression Profile Associated with Spontaneous Preterm Birth in Women with Threatened Preterm Labor
Yujing Jan Heng et al.
PLOS ONE (2014)
Dengue virus subgenomic RNA induces apoptosis through the Bcl-2-mediated PI3k/Akt signaling pathway
Yi Liu et al.
VIROLOGY (2014)
Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study
Anjali Shah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Ovarian cancer stem cells: Working towards the root of sternness
Rosemary Foster et al.
CANCER LETTERS (2013)
Dual Inhibition of Bcl-2 and Bcl-xL Strikingly Enhances PI3K Inhibition-Induced Apoptosis in Human Myeloid Leukemia Cells through a GSK3- and Bim-Dependent Mechanism
Mohamed Rahmani et al.
CANCER RESEARCH (2013)
Therapeutic targeting of c-KIT in cancer
Leonie K. Ashman et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia
Satomi Tanaka et al.
BLOOD (2012)
Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation
Richard L. Momparler et al.
LEUKEMIA RESEARCH (2012)
Expression Profiling of Human Immune Cell Subsets Identifies miRNA-mRNA Regulatory Relationships Correlated with Cell Type Specific Expression
Florence Allantaz et al.
PLOS ONE (2012)
Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer
Sarat Chandarlapaty
CANCER DISCOVERY (2012)
Compensatory Pathways in Oncogenic Kinase Signaling and Resistance to Targeted Therapies: Six Degrees of Separation
Livio Trusolino et al.
CANCER DISCOVERY (2012)
Coordinate PI3K pathway and Bcl-2 family disruption in AML
Prithviraj Bose et al.
ONCOTARGET (2012)
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity
Erdogan Taskesen et al.
BLOOD (2011)
Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome
Lijing Luo et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2011)
Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia
Brian V. Balgobind et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer
Francesco Crea et al.
MOLECULAR CANCER (2011)
Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as AML not otherwise specified (AML-NOS) or AML with myelodysplasia-related changes (AML-MRC)
Miriam Miesner et al.
BLOOD (2010)
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
Warren Fiskus et al.
BLOOD (2009)
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome
Bas J. Wouters et al.
BLOOD (2009)
Quantitative comparison of microarray experiments with published leukemia related gene expression signatures
Hans-Ulrich Klein et al.
BMC BIOINFORMATICS (2009)
Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling
Roel G. W. Verhaak et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
Tina Branscombe Miranda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes
Yanfang Guo et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2008)
An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia
Klaus H. Metzeler et al.
BLOOD (2008)
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia
Michael H. Tomasson et al.
BLOOD (2008)
Regulation of hematopoietic stem cells by the steel factor/KIT signaling pathway
David Kent et al.
CLINICAL CANCER RESEARCH (2008)
Kit regulates maintenance of quiescent hematopoietic stem cells
Lina A. Thoren et al.
JOURNAL OF IMMUNOLOGY (2008)
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Jeffrey A. Simon et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2008)
Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002
Jennifer F. Yamamoto et al.
CANCER CAUSES & CONTROL (2008)
PI3K is negatively regulated by PIK3IP1, a novel p110 interacting protein
Zhenqi Zhu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
Jing Tan et al.
GENES & DEVELOPMENT (2007)
Analysis of chromosome copy number in leukemic cells by different microarray platforms
Y. Yamashita et al.
LEUKEMIA (2007)
Stem cell c-KIT and HOXB4 genes:: Critical roles and mechanisms in self-renewal, proliferation, and differentiation
Shilpa Sharma et al.
STEM CELLS AND DEVELOPMENT (2006)
Role of histone H3 lysine 27 methylation in polycomb-group silencing
R Cao et al.
SCIENCE (2002)
Share Paper
